Pathological Complete Response to Lenvatinib After Failure of Atezolizumab Plus Bevacizumab in Unresectable Hepatocellular Carcinoma

Pathological Complete Response to Lenvatinib After Failure of Atezolizumab Plus Bevacizumab in Unresectable Hepatocellular Carcinoma

None

Guardado en:
Detalles Bibliográficos
Autores principales: Yusuke Johira, Tomokazu Kawaoka, Masanari Kosaka, Yuki Shirane, Ryoichi Miura, Serami Murakami, Shigeki Yano, Kei Amioka, Kensuke Naruto, Yuwa Ando, Yumi Kosaka, Kenichiro Kodama, Shinsuke Uchikawa, Hatsue Fujino, Atsushi Ono, Takashi Nakahara, Eisuke Murakami, Wataru Okamoto, Masami Yamauchi, Michio Imamura, Kazuhiro Sentani, Naohide Oue, Koji Arihiro, Shintaro Kuroda, Tsuyoshi Kobayashi, Hideki Ohdan, Kazuaki Chayama, Hiroshi Aikata
Formato: article
Lenguaje:EN
Publicado: Karger Publishers 2021
Materias:
Neoplasms. Tumors. Oncology. Including cancer and carcinogens
RC254-282
Acceso en línea:https://doaj.org/article/223812ca25cd4aecbe1ae5ead2c18af8
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
id oai:doaj.org-article:223812ca25cd4aecbe1ae5ead2c18af8
record_format dspace
spelling oai:doaj.org-article:223812ca25cd4aecbe1ae5ead2c18af82021-12-02T12:40:23ZPathological Complete Response to Lenvatinib After Failure of Atezolizumab Plus Bevacizumab in Unresectable Hepatocellular Carcinoma2235-17951664-555310.1159/000520898https://doaj.org/article/223812ca25cd4aecbe1ae5ead2c18af82021-11-01T00:00:00Zhttps://www.karger.com/Article/FullText/520898https://doaj.org/toc/2235-1795https://doaj.org/toc/1664-5553NoneYusuke JohiraTomokazu KawaokaMasanari KosakaYuki ShiraneRyoichi MiuraSerami MurakamiShigeki YanoKei AmiokaKensuke NarutoYuwa AndoYumi KosakaKenichiro KodamaShinsuke UchikawaHatsue FujinoAtsushi OnoTakashi NakaharaEisuke MurakamiWataru OkamotoMasami YamauchiMichio ImamuraKazuhiro SentaniNaohide OueKoji ArihiroShintaro KurodaTsuyoshi KobayashiHideki OhdanKazuaki ChayamaHiroshi AikataKarger PublishersarticleNeoplasms. Tumors. Oncology. Including cancer and carcinogensRC254-282ENLiver Cancer (2021)
institution DOAJ
collection DOAJ
language EN
topic Neoplasms. Tumors. Oncology. Including cancer and carcinogens
RC254-282
spellingShingle Neoplasms. Tumors. Oncology. Including cancer and carcinogens
RC254-282
Yusuke Johira
Tomokazu Kawaoka
Masanari Kosaka
Yuki Shirane
Ryoichi Miura
Serami Murakami
Shigeki Yano
Kei Amioka
Kensuke Naruto
Yuwa Ando
Yumi Kosaka
Kenichiro Kodama
Shinsuke Uchikawa
Hatsue Fujino
Atsushi Ono
Takashi Nakahara
Eisuke Murakami
Wataru Okamoto
Masami Yamauchi
Michio Imamura
Kazuhiro Sentani
Naohide Oue
Koji Arihiro
Shintaro Kuroda
Tsuyoshi Kobayashi
Hideki Ohdan
Kazuaki Chayama
Hiroshi Aikata
Pathological Complete Response to Lenvatinib After Failure of Atezolizumab Plus Bevacizumab in Unresectable Hepatocellular Carcinoma
description None
format article
author Yusuke Johira
Tomokazu Kawaoka
Masanari Kosaka
Yuki Shirane
Ryoichi Miura
Serami Murakami
Shigeki Yano
Kei Amioka
Kensuke Naruto
Yuwa Ando
Yumi Kosaka
Kenichiro Kodama
Shinsuke Uchikawa
Hatsue Fujino
Atsushi Ono
Takashi Nakahara
Eisuke Murakami
Wataru Okamoto
Masami Yamauchi
Michio Imamura
Kazuhiro Sentani
Naohide Oue
Koji Arihiro
Shintaro Kuroda
Tsuyoshi Kobayashi
Hideki Ohdan
Kazuaki Chayama
Hiroshi Aikata
author_facet Yusuke Johira
Tomokazu Kawaoka
Masanari Kosaka
Yuki Shirane
Ryoichi Miura
Serami Murakami
Shigeki Yano
Kei Amioka
Kensuke Naruto
Yuwa Ando
Yumi Kosaka
Kenichiro Kodama
Shinsuke Uchikawa
Hatsue Fujino
Atsushi Ono
Takashi Nakahara
Eisuke Murakami
Wataru Okamoto
Masami Yamauchi
Michio Imamura
Kazuhiro Sentani
Naohide Oue
Koji Arihiro
Shintaro Kuroda
Tsuyoshi Kobayashi
Hideki Ohdan
Kazuaki Chayama
Hiroshi Aikata
author_sort Yusuke Johira
title Pathological Complete Response to Lenvatinib After Failure of Atezolizumab Plus Bevacizumab in Unresectable Hepatocellular Carcinoma
title_short Pathological Complete Response to Lenvatinib After Failure of Atezolizumab Plus Bevacizumab in Unresectable Hepatocellular Carcinoma
title_full Pathological Complete Response to Lenvatinib After Failure of Atezolizumab Plus Bevacizumab in Unresectable Hepatocellular Carcinoma
title_fullStr Pathological Complete Response to Lenvatinib After Failure of Atezolizumab Plus Bevacizumab in Unresectable Hepatocellular Carcinoma
title_full_unstemmed Pathological Complete Response to Lenvatinib After Failure of Atezolizumab Plus Bevacizumab in Unresectable Hepatocellular Carcinoma
title_sort pathological complete response to lenvatinib after failure of atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma
publisher Karger Publishers
publishDate 2021
url https://doaj.org/article/223812ca25cd4aecbe1ae5ead2c18af8
work_keys_str_mv AT yusukejohira pathologicalcompleteresponsetolenvatinibafterfailureofatezolizumabplusbevacizumabinunresectablehepatocellularcarcinoma
AT tomokazukawaoka pathologicalcompleteresponsetolenvatinibafterfailureofatezolizumabplusbevacizumabinunresectablehepatocellularcarcinoma
AT masanarikosaka pathologicalcompleteresponsetolenvatinibafterfailureofatezolizumabplusbevacizumabinunresectablehepatocellularcarcinoma
AT yukishirane pathologicalcompleteresponsetolenvatinibafterfailureofatezolizumabplusbevacizumabinunresectablehepatocellularcarcinoma
AT ryoichimiura pathologicalcompleteresponsetolenvatinibafterfailureofatezolizumabplusbevacizumabinunresectablehepatocellularcarcinoma
AT seramimurakami pathologicalcompleteresponsetolenvatinibafterfailureofatezolizumabplusbevacizumabinunresectablehepatocellularcarcinoma
AT shigekiyano pathologicalcompleteresponsetolenvatinibafterfailureofatezolizumabplusbevacizumabinunresectablehepatocellularcarcinoma
AT keiamioka pathologicalcompleteresponsetolenvatinibafterfailureofatezolizumabplusbevacizumabinunresectablehepatocellularcarcinoma
AT kensukenaruto pathologicalcompleteresponsetolenvatinibafterfailureofatezolizumabplusbevacizumabinunresectablehepatocellularcarcinoma
AT yuwaando pathologicalcompleteresponsetolenvatinibafterfailureofatezolizumabplusbevacizumabinunresectablehepatocellularcarcinoma
AT yumikosaka pathologicalcompleteresponsetolenvatinibafterfailureofatezolizumabplusbevacizumabinunresectablehepatocellularcarcinoma
AT kenichirokodama pathologicalcompleteresponsetolenvatinibafterfailureofatezolizumabplusbevacizumabinunresectablehepatocellularcarcinoma
AT shinsukeuchikawa pathologicalcompleteresponsetolenvatinibafterfailureofatezolizumabplusbevacizumabinunresectablehepatocellularcarcinoma
AT hatsuefujino pathologicalcompleteresponsetolenvatinibafterfailureofatezolizumabplusbevacizumabinunresectablehepatocellularcarcinoma
AT atsushiono pathologicalcompleteresponsetolenvatinibafterfailureofatezolizumabplusbevacizumabinunresectablehepatocellularcarcinoma
AT takashinakahara pathologicalcompleteresponsetolenvatinibafterfailureofatezolizumabplusbevacizumabinunresectablehepatocellularcarcinoma
AT eisukemurakami pathologicalcompleteresponsetolenvatinibafterfailureofatezolizumabplusbevacizumabinunresectablehepatocellularcarcinoma
AT wataruokamoto pathologicalcompleteresponsetolenvatinibafterfailureofatezolizumabplusbevacizumabinunresectablehepatocellularcarcinoma
AT masamiyamauchi pathologicalcompleteresponsetolenvatinibafterfailureofatezolizumabplusbevacizumabinunresectablehepatocellularcarcinoma
AT michioimamura pathologicalcompleteresponsetolenvatinibafterfailureofatezolizumabplusbevacizumabinunresectablehepatocellularcarcinoma
AT kazuhirosentani pathologicalcompleteresponsetolenvatinibafterfailureofatezolizumabplusbevacizumabinunresectablehepatocellularcarcinoma
AT naohideoue pathologicalcompleteresponsetolenvatinibafterfailureofatezolizumabplusbevacizumabinunresectablehepatocellularcarcinoma
AT kojiarihiro pathologicalcompleteresponsetolenvatinibafterfailureofatezolizumabplusbevacizumabinunresectablehepatocellularcarcinoma
AT shintarokuroda pathologicalcompleteresponsetolenvatinibafterfailureofatezolizumabplusbevacizumabinunresectablehepatocellularcarcinoma
AT tsuyoshikobayashi pathologicalcompleteresponsetolenvatinibafterfailureofatezolizumabplusbevacizumabinunresectablehepatocellularcarcinoma
AT hidekiohdan pathologicalcompleteresponsetolenvatinibafterfailureofatezolizumabplusbevacizumabinunresectablehepatocellularcarcinoma
AT kazuakichayama pathologicalcompleteresponsetolenvatinibafterfailureofatezolizumabplusbevacizumabinunresectablehepatocellularcarcinoma
AT hiroshiaikata pathologicalcompleteresponsetolenvatinibafterfailureofatezolizumabplusbevacizumabinunresectablehepatocellularcarcinoma
_version_ 1718393729487732736

Ejemplares similares